Thursday, June 20, 2019
AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019
LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 20, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and...

  Tuesday, June 4, 2019
AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 4, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, will...

  Monday, June 3, 2019
AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.
LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 3, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC ® fluid...

  Tuesday, May 28, 2019
AngioDynamics to Ring NASDAQ Closing Bell to Celebrate the 15th Anniversary of its Listing on the Exchange
LATHAM, N.Y. --(BUSINESS WIRE)--May 28, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock...

  Wednesday, May 22, 2019
AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer
LATHAM, N.Y. --(BUSINESS WIRE)--May 22, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration ( FDA )...

  Monday, May 13, 2019
AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer
LATHAM, N.Y. --(BUSINESS WIRE)--May 13, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced enrollment of the first patient in its NanoKnife ® Irreversible...

  Wednesday, April 17, 2019
AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million
AngioDynamics to host conference call today at 5:00 p.m. ET LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that...

  Wednesday, April 17, 2019
AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer
LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB)...

  Tuesday, April 2, 2019
AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results
Fiscal 2019 Third Quarter Highlights Net sales of $86.3 million , an increase of 3.0% year over year Gross margin declined 10 basis points year over year to 54.1% GAAP EPS of $0.02 per share; adjusted EPS of $0.19 per share Cash provided by operations of $8.3 million ; capital expenditures of $0.9...

  Monday, April 1, 2019
AngioDynamics to Present at the Needham Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner , Executive Vice President and Chief...

  Monday, April 1, 2019
AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer
LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration ( FDA ) approved...

  Thursday, March 28, 2019
CORRECTING and REPLACING OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy
LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 28, 2019-- Second paragraph, first sentence of release should read: The additional indications clear the OARtrac System for use with patient-specific, pre-calibrated Plastic Scintillating Detector (PSD) sensors used during cancer treatments to measure photon and...

  Tuesday, March 12, 2019
AngioDynamics to Report Fiscal 2019 Third Quarter Financial Results on April 2, 2019
LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 12, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of...

  Friday, March 8, 2019
AngioDynamics Wins Patent Infringement Dispute With Bard
LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 8, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware ,...

  Tuesday, February 26, 2019
AngioDynamics to Present at the Barclays Global Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 26, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and...